Unknown
Scott Canna, MD (he/him/his)
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Disclosure(s): Apollo Therapeutics: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Site PI for industry-sponsored trial (Ongoing); PracticePoint CME: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Simcha Therapeutics: Consultant (Terminated, December 31, 2022); Sobi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, May 31, 2023)
Hanna Kim, MD,MS
NIAMS, NIH
Bethesda, MD, United States
Disclosure(s): No relevant disclosure to display
Research to better understand pediatric rheumatologic disease has evolved to the evaluation of comprehensive expression of proteins and genes with technical advances, with the term of "omic" experiments, and more recently at single-cell resolution. This allows for better evaluation of what different cell populations are doing and how that changes over time with disease. The goal of this session is to review how this technology has been utilized in pediatric rheumatology and how that translates to better understanding of disease.
Speaker: Peter Nigrovic, MD – Boston Children's Hospital
Speaker: Jessica Neely, MD – UCSF